Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $175,585.68 in Stock

Key Points

• Insider David Malcom Rodman sold 6,348 shares on April 15 at an average price of $27.66 for $175,585.68, reducing his direct holdings to 69,792 shares (an 8.34% decrease); the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• Rodman has repeatedly sold shares in recent months across multiple transactions (including sizable sales on April 13 and several dates in Feb–Mar), indicating sustained insider selling activity.
• MLYS traded at $30.42 with heavy volume on the day, reported a narrower-than-expected quarterly loss (EPS -$0.40 vs. -$0.57 est.), and carries a consensus analyst rating of "Moderate Buy" with a $49.14 target amid mixed individual ratings.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $27.66, for a total transaction of $175,585.68. Following the transaction, the insider directly owned 69,792 shares in the company, valued at approximately $1,930,446.72. This represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total transaction of $373,099.32.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total value of $59,414.60.
• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total value of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total value of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.
• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total value of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total value of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total value of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total value of $13,353.60.

Mineralys Therapeutics Stock Performance

MLYS stock traded up $3.10 during mid-day trading on Wednesday, hitting $30.42. 3,180,291 shares of the company were exchanged, compared to its average volume of 1,310,737. Mineralys Therapeutics, Inc. has a 1-year low of $12.59 and a 1-year high of $47.65. The firm's 50 day simple moving average is $27.26 and its 200 day simple moving average is $34.36. The firm has a market cap of $2.51 billion, a P/E ratio of -12.84 and a beta of 0.69.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. On average, equities research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Ratings Changes

MLYS has been the subject of a number of research analyst reports. HC Wainwright set a $56.00 target price on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Jefferies Financial Group reissued a "hold" rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Friday, March 13th. Bank of America boosted their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a "buy" rating in a report on Friday, March 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $49.14.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. grew its position in shares of Mineralys Therapeutics by 19.1% in the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company's stock valued at $277,717,000 after acquiring an additional 1,176,470 shares during the period. Vanguard Group Inc. lifted its stake in Mineralys Therapeutics by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company's stock valued at $121,676,000 after purchasing an additional 333,881 shares during the last quarter. State Street Corp lifted its stake in Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company's stock valued at $115,584,000 after purchasing an additional 1,881,976 shares during the last quarter. Caligan Partners LP grew its holdings in Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company's stock worth $105,139,000 after purchasing an additional 755,302 shares during the period. Finally, Suvretta Capital Management LLC grew its holdings in Mineralys Therapeutics by 22.2% during the third quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company's stock worth $80,850,000 after purchasing an additional 387,641 shares during the period. Institutional investors and hedge funds own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.